Coherus Oncology (CHRS) Short-term Investments (2017 - 2026)

Coherus Oncology has reported Short-term Investments for 9 years, with the latest figure at $51.8 million in Q1 2026.

• Quarterly Short-term Investments changed N/A year-over-year to $51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.8 million (changed N/A YoY) and the FY2025 annual result came in at $83.2 million, changed N/A from the prior year.
• Short-term Investments eased to $51.8 million in Q1 2026 per CHRS's latest filing, from $83.2 million in the prior quarter.
• Over five years, Short-term Investments peaked at $128.1 million in Q4 2022 and troughed at $14.9 million in Q4 2023.
• A 4-year average of $69.1 million and a median of $71.8 million in 2023 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 88.41% in 2023, down 88.41% in 2023.
• Over 4 years, Short-term Investments stood at $128.1 million in 2022, then sank by 88.41% to $14.9 million in 2023, then jumped by 460.32% to $83.2 million in 2025, then tumbled by 37.76% to $51.8 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $51.8 million, $83.2 million, and $88.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.